Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Comparative nutritional and chemical phenome of Clostridium difficile isolates determined using phenotype microarrays.

Scaria J, Chen JW, Useh N, He H, McDonough SP, Mao C, Sobral B, Chang YF.

Int J Infect Dis. 2014 Oct;27:20-5. doi: 10.1016/j.ijid.2014.06.018. Epub 2014 Aug 12.

2.

Regulation of Type IV Pili Contributes to Surface Behaviors of Historical and Epidemic Strains of Clostridium difficile.

Purcell EB, McKee RW, Bordeleau E, Burrus V, Tamayo R.

J Bacteriol. 2015 Nov 23;198(3):565-77. doi: 10.1128/JB.00816-15.

3.

The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains.

Dawson LF, Donahue EH, Cartman ST, Barton RH, Bundy J, McNerney R, Minton NP, Wren BW.

BMC Microbiol. 2011 Apr 28;11:86. doi: 10.1186/1471-2180-11-86.

4.

Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile.

Ðapa T, Leuzzi R, Ng YK, Baban ST, Adamo R, Kuehne SA, Scarselli M, Minton NP, Serruto D, Unnikrishnan M.

J Bacteriol. 2013 Feb;195(3):545-55. doi: 10.1128/JB.01980-12. Epub 2012 Nov 21.

5.

Outcome of relapsing Clostridium difficile infections do not correlate with virulence-, spore- and vegetative cell-associated phenotypes.

Plaza-Garrido Á, Miranda-Cárdenas C, Castro-Córdova P, Olguín-Araneda V, Cofré-Araneda G, Hernández-Rocha C, Carman R, Ibáñez P, Fawley WN, Wilcox MH, Gil F, Calderón IL, Fuentes JA, Guzmán-Durán AM, Alvarez-Lobos M, Paredes-Sabja D.

Anaerobe. 2015 Dec;36:30-8. doi: 10.1016/j.anaerobe.2015.09.005. Epub 2015 Sep 25.

PMID:
26403333
6.

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.

Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ.

J Antimicrob Chemother. 2015;70(6):1751-6. doi: 10.1093/jac/dkv006. Epub 2015 Feb 3.

7.

Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains.

Stabler RA, Gerding DN, Songer JG, Drudy D, Brazier JS, Trinh HT, Witney AA, Hinds J, Wren BW.

J Bacteriol. 2006 Oct;188(20):7297-305.

8.

Clostridium difficile and the disease it causes.

Norén T.

Methods Mol Biol. 2010;646:9-35. doi: 10.1007/978-1-60327-365-7_2.

PMID:
20597000
9.

Update on Clostridium difficile associated disease.

Cloud J, Kelly CP.

Curr Opin Gastroenterol. 2007 Jan;23(1):4-9. Review.

PMID:
17133077
10.

Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Sirard S, Valiquette L, Fortier LC.

J Clin Microbiol. 2011 Dec;49(12):4040-6. doi: 10.1128/JCM.05053-11. Epub 2011 Sep 28.

11.

A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.

Gebhart D, Lok S, Clare S, Tomas M, Stares M, Scholl D, Donskey CJ, Lawley TD, Govoni GR.

MBio. 2015 Mar 24;6(2). pii: e02368-14. doi: 10.1128/mBio.02368-14.

12.

The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.

Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB.

Gut Microbes. 2011 May-Jun;2(3):145-58. Epub 2011 May 1.

13.

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

Baines SD, Saxton K, Freeman J, Wilcox MH.

J Antimicrob Chemother. 2006 Nov;58(5):1062-5. Epub 2006 Oct 8.

PMID:
17030519
14.

Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.

Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ; ECDIS Study Group..

J Antimicrob Chemother. 2013 Jun;68(6):1305-11. doi: 10.1093/jac/dkt013. Epub 2013 Feb 18.

PMID:
23420839
15.

Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.

Baines SD, Noel AR, Huscroft GS, Todhunter SL, O'Connor R, Hobbs JK, Freeman J, Lovering AM, Wilcox MH.

J Antimicrob Chemother. 2011 Jul;66(7):1537-46. doi: 10.1093/jac/dkr155. Epub 2011 Apr 18.

PMID:
21504940
16.

In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.

Chilton CH, Crowther GS, Baines SD, Todhunter SL, Freeman J, Locher HH, Athanasiou A, Wilcox MH.

J Antimicrob Chemother. 2014 Mar;69(3):697-705. doi: 10.1093/jac/dkt411. Epub 2013 Oct 14.

PMID:
24128668
17.

Case fatality associated with a hypervirulent strain in patients with culture-positive Clostridium difficile infection: a retrospective population-based study.

Huttunen R, Vuento R, Syrjänen J, Tissari P, Aittoniemi J.

Int J Infect Dis. 2012 Jul;16(7):e532-5. doi: 10.1016/j.ijid.2012.02.019. Epub 2012 May 7.

19.

Clostridium difficile infection in an Iranian hospital.

Jalali M, Khorvash F, Warriner K, Weese JS.

BMC Res Notes. 2012 Mar 21;5:159. doi: 10.1186/1756-0500-5-159.

20.

Update on antimicrobial resistance in Clostridium difficile.

Qiong G, Haihui H.

Yi Chuan. 2015 May;37(5):458-64. doi: 10.16288/j.yczz.15-131. Review.

PMID:
25998434

Supplemental Content

Support Center